Core Viewpoint - The company, Shanghai MicroPort CardioFlow Medtech Co., Ltd., is experiencing a decline in revenue and net profit, with a notable drop in its stock price and market valuation compared to industry averages [1][2]. Company Overview - The main business of the company includes the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [2]. - Key products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, intraoperative stents, balloon catheters, and stents [2]. - The company has received several awards, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2]. Financial Performance - For Q1 2025, the company reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% [2]. - The gross profit margin stands at 69.61% [2]. Market Position - As of the latest data, the company's rolling price-to-earnings (PE) ratio is 32.83, while the industry average PE is 55.91, indicating a lower valuation compared to peers [1][3]. - The total market capitalization of the company is 14.692 billion yuan [1].

Group 1 - The core business of the company is the research, production, and sales of interventional medical devices for aorta and peripheral blood vessels [2] - The company reported a revenue of 332 million yuan for Q1 2025, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% year-on-year, with a gross margin of 69.61% [2] - The company's current stock price is 120.28 yuan, with a PE ratio of 33.14 and a total market capitalization of 14.826 billion yuan [1][3] Group 2 - The average PE ratio for the medical device industry is 59.32, with a median of 39.97, placing the company at the 65th position in the industry ranking [1][3] - The company has received several awards, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2] - The company has five institutional holders, including four funds and one brokerage, with a total holding of 324,900 shares valued at 2.9 million yuan [1]

8月14日，心脉医疗今日收盘115.7元，下跌4.40%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到31.87倍，总市值142.61亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，心脉医疗排 名第64位。 截至2025年一季报，共有5家机构持仓心脉医疗，其中基金4家、券商1家，合计持股数32.49万股，持股 市值0.29亿元。 上海微创心脉医疗科技(集团)股份有限公司的主营业务是主动脉及外周血管介入医疗器械的研发、生产 和销售。公司的主要产品是胸主动脉覆膜支架系统、腹主动脉覆膜支架系统、术中支架类、球囊类、支 架类。公司获评上海市政府质量金奖、科创板公司价值30强、首届"未来20·中国A股上市公司成长力年 度企业"；子公司鸿脉、蓝脉、拓脉获评"科技型中小企业"，蓝脉首次通过高新技术企业认定并获评"张 江年度新锐"企业；Castor分支型胸主动脉覆膜支架进入国家知识产权局《第二十五届中国专利金奖预 获奖项目》公示名录;静脉支架等入选《上海市"新优药械"产品目录》和《浦东新区创新药械产品推荐 目录》，另有5个项目获评浦东职工科技创新项目。总裁朱清 ...

上海微创心脉医疗科技(集团)股份有限公司的主营业务是主动脉及外周血管介入医疗器械的研发、生产 和销售。公司的主要产品是胸主动脉覆膜支架系统、腹主动脉覆膜支架系统、术中支架类、球囊类、支 架类。公司获评上海市政府质量金奖、科创板公司价值30强、首届"未来20·中国A股上市公司成长力年 度企业"；子公司鸿脉、蓝脉、拓脉获评"科技型中小企业"，蓝脉首次通过高新技术企业认定并获评"张 江年度新锐"企业；Castor分支型胸主动脉覆膜支架进入国家知识产权局《第二十五届中国专利金奖预 获奖项目》公示名录;静脉支架等入选《上海市"新优药械"产品目录》和《浦东新区创新药械产品推荐 目录》，另有5个项目获评浦东职工科技创新项目。总裁朱清入选"明珠领军人才"，刘梦钦、王金耀、 屠春霖、樊亚明入选"明珠工程师"。 最新一期业绩显示，2025年一季报，公司实现营业收入3.32亿元，同比-7.23%；净利润1.30亿元，同 比-29.66%，销售毛利率69.61%。 8月12日，心脉医疗今日收盘120.0元，上涨1.55%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到33.06倍，创162天以来新低，总市值147.91 ...

Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. specializes in the research, production, and sales of interventional medical devices for aortic and peripheral vascular applications [2] - The main products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, intraoperative stents, balloon catheters, and stents [2] - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2] Financial Performance - For Q1 2025, the company reported revenue of 332 million yuan, a year-on-year decrease of 7.23% [2] - The net profit for the same period was 130 million yuan, down 29.66% year-on-year, with a gross profit margin of 69.61% [2] Market Position - As of August 5, the company's stock closed at 111.89 yuan, down 1.37%, with a rolling PE ratio of 30.82 times [1] - The average PE ratio for the medical device industry is 54.24 times, with a median of 37.92 times, placing the company at 61st in industry rankings [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 18,176, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

Core Viewpoint - The company, Xinmai Medical, has shown a slight increase in stock price and has a lower price-to-earnings (PE) ratio compared to the industry average, indicating potential investment opportunities despite recent declines in revenue and profit [1][2]. Company Overview - Xinmai Medical specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with key products including aortic stent graft systems and balloon catheters [2]. - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2]. Financial Performance - For Q1 2025, Xinmai Medical reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% from the previous year, with a gross margin of 69.61% [2]. Market Position - As of the latest data, Xinmai Medical's PE ratio stands at 31.25, while the industry average is 54.32, indicating that the company is undervalued relative to its peers [3]. - The total market capitalization of Xinmai Medical is approximately 13.983 billion yuan [1][3].

7月30日，心脉医疗今日收盘111.61元，下跌2.09%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到30.75倍，总市值137.57亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.15倍，行业中值37.48倍，心脉医疗排 名第61位。 股东方面，截至2025年3月31日，心脉医疗股东户数18176户，较上次增加523户，户均持股市值35.28万 元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13心脉医疗30.7527.403.58137.57亿行业平均 55.1550.114.80115.74亿行业中值37.4836.822.6955.61亿1九安医疗11.0711.200.87186.87亿2英科医疗 14.0715.171.25222.33亿3新华医疗15.9114.751.30101.98亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2116.261.86153.29亿6奥美医疗16.3215.991.6858.96亿7康德莱17.1917.201.4237.04亿8九强生物 17.5016.272. ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Xinmai Medical, which closed at 101.93 yuan with a PE ratio of 28.08, significantly lower than the industry average of 53.52 [1][3] - Xinmai Medical specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with key products including stent systems and balloon catheters [2] - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 companies in the Sci-Tech Innovation Board [2] Group 2 - As of the first quarter of 2025, Xinmai Medical reported a revenue of 3.32 billion yuan, a year-on-year decrease of 7.23%, and a net profit of 1.30 billion yuan, down 29.66%, with a gross margin of 69.61% [2] - The company ranks 57th in terms of PE ratio within its industry, indicating a relatively lower valuation compared to peers [1][3] - Four institutions hold shares in Xinmai Medical, with a total of 89,200 shares valued at 0.08 billion yuan [1]

Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [2] - The main products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, intraoperative stents, balloon catheters, and stents [2] Recent Performance - As of the first quarter of 2025, the company reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% year-on-year [2] - The sales gross margin stands at 69.61% [2] Market Position - The company's stock closed at 95.92 yuan, with a rolling price-to-earnings (PE) ratio of 26.42, marking a new low in 67 days [1] - The total market capitalization is 11.823 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 52.06, with a median of 37.22, placing the company at the 57th position in the industry ranking [1][3] Institutional Holdings - As of the first quarter of 2025, 11 institutions hold shares in the company, including 5 funds, 4 others, 1 brokerage, and 1 social security fund, with a total holding of 56.5791 million shares valued at 5.098 billion yuan [1]

上海微创心脉医疗科技(集团)股份有限公司的主营业务是主动脉及外周血管介入医疗器械的研发、生产 和销售。公司的主要产品是胸主动脉覆膜支架系统、腹主动脉覆膜支架系统、术中支架类、球囊类、支 架类。公司获评上海市政府质量金奖、科创板公司价值30强、首届"未来20·中国A股上市公司成长力年 度企业"；子公司鸿脉、蓝脉、拓脉获评"科技型中小企业"，蓝脉首次通过高新技术企业认定并获评"张 江年度新锐"企业；Castor分支型胸主动脉覆膜支架进入国家知识产权局《第二十五届中国专利金奖预 获奖项目》公示名录;静脉支架等入选《上海市"新优药械"产品目录》和《浦东新区创新药械产品推荐 目录》，另有5个项目获评浦东职工科技创新项目。总裁朱清入选"明珠领军人才"，刘梦钦、王金耀、 屠春霖、樊亚明入选"明珠工程师"。 最新一期业绩显示，2025年一季报，公司实现营业收入3.32亿元，同比-7.23%；净利润1.30亿元，同 比-29.66%，销售毛利率69.61%。 7月7日，心脉医疗今日收盘92.06元，下跌2.73%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到25.36倍，总市值113.48亿元。 序号股票简称P ...